Schizophrenia Treatment

Schizophrenia Treatment: Integrated Medications and Psychosocial Care

Schizophrenia is highly treatable. With modern antipsychotic medications combined with psychosocial support, most individuals with schizophrenia achieve substantial symptom reduction and functional improvement. This comprehensive guide explains treatment options at KwikPsych.

Treatment Philosophy

Modern schizophrenia treatment recognizes that medications alone are insufficient. Optimal outcomes require:

1. Antipsychotic medication: Targets psychotic symptoms
2. Psychoeducation: Understanding illness and treatment
3. Psychosocial rehabilitation: Rebuilding functioning
4. Supported employment: Work and vocational support
5. Family involvement: Education and support
6. Substance use treatment: If applicable
7. Medical monitoring: Metabolic, cardiovascular, neurological

Antipsychotic Medications

Second-Generation (Atypical) Antipsychotics: First-Line Treatment

Second-generation antipsychotics (SGAs) are now standard first-line treatment for schizophrenia, offering superior negative symptom efficacy and lower extrapyramidal side effect risk compared to first-generation antipsychotics.

Common Second-Generation Antipsychotics

Risperidone (Risperdal)

• Typical dose: 4-6 mg daily (divided)
• Mechanism: D2 and 5-HT2A receptor antagonist
• Advantages: Effective positive and negative symptoms, available IM injection
• Side effects: Prolactin elevation, weight gain, metabolic effects
• Monitoring: Prolactin, metabolic panel, EPS
• Combination: Works well with psychosocial treatments
• First-episode: Often first choice

Olanzapine (Zyprexa)

• Typical dose: 10-20 mg daily
• Mechanism: D2, 5-HT2A, muscarinic antagonism
• Advantages: Highly effective, particularly for positive symptoms
• Side effects: Significant weight gain, metabolic effects (diabetes risk), sedation
• Monitoring: Weight, glucose, lipids, EPS
• Best for: Severe positive symptoms despite risks
• Caution: Metabolic side effects limit use in some

Quetiapine (Seroquel)

• Typical dose: 300-800 mg daily (divided)
• Mechanism: D2, 5-HT2A antagonism, antihistamine effect
• Advantages: Sedating (helpful if insomnia), lower EPS/prolactin risk, versatile
• Side effects: Sedation, weight gain, orthostatic hypotension
• Best for: Schizophrenia with insomnia or agitation
• Note: Higher doses required than for mood disorders

Aripiprazole (Abilify)

• Typical dose: 10-15 mg daily
• Mechanism: D2 partial agonist (unique mechanism)
• Advantages: Minimal weight gain, prolactin normal, activating, good tolerability
• Side effects: Akathisia (restlessness) possible, insomnia in some, less sedating
• Best for: Patients concerned about weight/metabolic effects
• Drug interactions: Few significant ones
• Availability: Many formulations including monthly IM injection

Paliperidone (Invega)

• Typical dose: 6-12 mg daily
• Mechanism: D2 and 5-HT2A antagonist (risperidone's active metabolite)
• Advantages: Extended-release formulations, IM monthly/3-month injections available
• Side effects: Similar to risperidone, prolactin elevation
• Best for: Patients needing long-acting injection
• Monitoring: Similar to risperidone

Lurasidone (Latuda)

• Typical dose: 40-160 mg daily
• Mechanism: D2 and 5-HT2A antagonist
• Advantages: Minimal weight gain, minimal metabolic effects, good tolerability
• Side effects: Nausea (especially without food), akathisia possible
• Best for: Weight/metabolic concern; depression component
• Important: Must take with food (absorption requires fat)

Iloperidone (Fanapt)

• Typical dose: 12-24 mg daily (divided)
• Mechanism: D2 and 5-HT2A antagonist
• Advantages: Low weight gain, minimal prolactin elevation
• Side effects: Orthostatic hypotension (slow titration required), tachycardia possible
• Best for: Alternative when others poorly tolerated
• Titration: Must escalate slowly (week 1-2 week protocol)

First-Generation (Typical) Antipsychotics: Selective Use

Still occasionally used when cost is primary concern or as adjuncts:

Haloperidol (Haldol)

• Typical dose: 5-20 mg daily
• Advantages: Inexpensive, highly effective for acute agitation
• Disadvantages: High EPS risk, less effective for negative symptoms
• Use: Acute management, cost-limited access
• Caution: Risk of tardive dyskinesia with long-term use

Chlorpromazine

• Typical dose: 300-1000 mg daily
• Historic use: First antipsychotic developed
• Current role: Limited due to side effects
• Issues: High EPS, sedation, weight gain, liver effects

Treatment-Resistant Schizophrenia: Clozapine

When 2-3 antipsychotic trials fail, clozapine becomes critical option.

Clozapine (Clozaril)

• Typical dose: 300-900 mg daily
• Mechanism: D1/D2 antagonism, unique serotonergic profile
• Indications:
• Failure of 2+ antipsychotics
• High suicide risk
• Severe symptoms unresponsive to other agents

Advantages (Powerful Benefits):

• Most effective for treatment-resistant symptoms
• Unique effect on negative symptoms and cognitive function
• Significantly reduces suicidal behavior
• Unique mechanism may help when others fail

Disadvantages (Significant Monitoring Required):

• Agranulocytosis (0.8-1% risk): Dangerous drop in white blood cells
• Requires baseline and regular blood count monitoring
• Myocarditis (heart inflammation) risk: Requires EKG monitoring
• Seizure risk (dose-dependent)
• Orthostatic hypotension: Can cause falls
• Sedation and weight gain significant
• Complex pharmacokinetics

Monitoring Protocol (FDA-Mandated):

• Baseline: EKG, white blood cell count (WBC), absolute neutrophil count (ANC)
• First 6 months: Weekly WBC/ANC
• Months 6-12: Every 2 weeks WBC/ANC
• Beyond 12 months: Monthly WBC/ANC
• Ongoing EKG monitoring per protocol

Who Uses Clozapine:

• Requires psychiatrist experienced with clozapine
• Requires patient motivation for blood work compliance
• Requires access to regular monitoring
• KwikPsych can manage clozapine treatment with coordination of blood work

Clozapine's Unique Benefits:

For patients tolerating monitoring, clozapine offers hope when nothing else worked. Transformative for some.

Long-Acting Injectable (LAI) Antipsychotics

Injectable antipsychotics administered every 2-4 weeks provide medication adherence assurance and improved outcomes.

Advantages of LAI:

• Adherence guaranteed (no daily pill burden)
• Prevents relapse from medication non-compliance
• Improved outcomes in some studies
• Only requires every 2-4 week visit
• Sustained antipsychotic levels

Available Options:

Risperidone IM (Risperdal Consta):

• Frequency: Every 2 weeks
• Dose: 25-50 mg IM
• Onset: 3 weeks to full effect
• Coverage: Continue oral risperidone during initiation

Paliperidone Palmitate (Invega Sustenna):

• Frequency: Monthly
• Dose: 39-234 mg IM
• Onset: 3-4 weeks to full effect
• Long half-life ensures sustained coverage

Paliperidone 3-Month Injection (Invega Trinza):

• Frequency: Every 3 months
• Requires monthly injections x 4 first
• Great option for stable patients wanting fewer visits

Aripiprazole IM (Abilify Maintena):

• Frequency: Monthly
• Dose: 300-400 mg IM
• Onset: Faster than others
• Continue oral aripiprazole initially

Aripiprazole 3-Month (Abilify Asimtufii):

• Frequency: Every 3 months
• Similar benefits to monthly
• Requires oral lead-in period

When LAI Considered:

• First-episode psychosis (after stabilization)
• History of medication non-compliance
• Multiple relapses from stopping medications
• Patient preference
• Difficulty with daily pill regimen

Antipsychotic Selection Principles

Factors guiding choice:

Clinical presentation:

• Predominant positive symptoms: Risperidone, olanzapine, paliperidone
• Negative/cognitive prominent: Aripiprazole, lurasidone
• Severe agitation: Quetiapine, olanzapine
• Suicidality: Clozapine (specific indication)

Side effect profile:

• Weight gain concern: Aripiprazole, lurasidone, quetiapine (lower)
• Metabolic risk: Aripiprazole, lurasidone, quetiapine
• Movement disorder risk: Quetiapine, aripiprazole (lower)
• Prolactin concern: Aripiprazole (no elevation), lurasidone (minimal)
• Sedation desired: Quetiapine, olanzapine
• Activation needed: Aripiprazole

Patient factors:

• Age and medical comorbidities
• Prior medication responses
• Family history of side effects
• Pregnancy/breastfeeding status
• Drug interactions
• Cost/insurance
• Preference and adherence

First-episode approach:

• Start low, go slow (titrate gradually)
• Allow 6-8 weeks at therapeutic dose before assessing efficacy
• Oral preferred initially unless severe agitation requires IM
• Monotherapy preferred (combination increases side effects)

Monitoring During Treatment

Metabolic Monitoring

Annual assessment essential:

• Weight and BMI at each visit
• Waist circumference
• Blood glucose (fasting preferred) or HbA1c
• Lipid panel (cholesterol, triglycerides)
• Blood pressure

Neurological Monitoring

• Extrapyramidal side effects: Movement disorders assessment
• Tardive dyskinesia: Abnormal involuntary movement scale (AIMS) annually
• Seizure threshold: Especially with clozapine

Endocrine Monitoring

• Prolactin levels if concerned (risperidone, paliperidone, amisulpride elevate)
• Menstrual history if female
• Sexual function assessment

Cardiac Monitoring

• Baseline EKG (especially risperidone, quetiapine, clozapine)
• QTc interval assessment
• Ongoing if high dose or risk factors

Labs and Monitoring Schedule

Baseline (before starting):

• Fasting glucose or HbA1c
• Lipid panel
• Prolactin (optional baseline)
• EKG (especially if QTc concern)
• Weight, BMI, waist circumference

During initiation (first month):

• Weight at each visit
• Side effect assessment
• Tolerability check

Maintenance (ongoing):

• Weight/BMI and metabolic panel annually
• EPS assessment per visit
• Prolactin if symptoms develop
• Blood pressure and pulse each visit
• Medication compliance assessment

Psychosocial Interventions

Medications address biology; psychosocial interventions address functioning:

Psychoeducation

For patient:

• Understanding psychosis and schizophrenia
• Medication mechanism and importance
• Side effects and management
• Relapse warning signs
• Importance of medication adherence
• Substance use risks

For family:

• Understanding illness
• Communication strategies
• Stress reduction
• Problem-solving
• Relapse prevention
• Caregiver self-care

Cognitive-Behavioral Therapy (CBT)

Components:

• Reality testing for persistent delusions
• Coping strategies for hallucinations
• Thought challenge techniques
• Behavioral activation
• Social skills training
• Relapse prevention

Efficacy:

• Modest effects on positive symptoms
• Better for residual symptoms
• Particularly helpful with depression/anxiety

Supported Employment

Assertive Community Treatment approach:

• Competitive, integrated employment goal
• Individualized job coaching
• Employer liaison
• Benefits counseling (SVR-SSDI)
• Ongoing support

Outcomes:

• 50-70% competitive employment rates vs. 10-20% sheltered work
• Improved self-esteem and functioning
• Better income
• Improved prognosis

Social Skills Training

Focus:

• Conversation and communication
• Problem-solving and conflict resolution
• Medication management and healthcare participation
• Recreation and leisure
• Independent living skills (cooking, shopping, budgeting)

Delivery:

• Individual or group
• Behavioral rehearsal and practice
• Homework assignments
• Generalization to community

Assertive Community Treatment (ACT)

For high-need individuals:

• Multidisciplinary team
• Home-based services
• Frequent contact (multiple visits/week)
• 24/7 crisis coverage
• Comprehensive services (psychiatric, medical, vocational, housing)

Outcomes:

• Better housing stability
• Fewer hospitalizations
• Improved employment
• Better quality of life

Crisis Management and Hospitalization

When hospitalization needed:

• Imminent risk to self or others
• Complete inability to care for self
• Medication non-compliance threatening safety
• Acute severe symptoms uncontrolled in community

Hospitalization benefits:

• Safe environment
• Intensive medication management
• Rapid stabilization
• Family education
• Discharge planning with community care coordination

Substance Use and Schizophrenia

Comorbid substance use extremely common (50-70% lifetime):

Cannabis:

• Increased psychosis risk
• Worsens symptoms
• Interferes with medication
• Avoid strongly recommended

Stimulants (methamphetamine, cocaine):

• Severe psychosis exacerbation
• Dangerous combination with antipsychotics
• Avoid

Alcohol:

• Increased relapse risk
• Liver effects with medications
• Self-medication pattern common
• Treatment needed

Treatment approach:

• Motivational interviewing
• Cognitive-behavioral therapy for substance use
• Peer support (AA, NA)
• Dual diagnosis programs when available
• Medication-assisted treatment if opioid use

Treating Co-occurring Conditions

Depression

Common in schizophrenia:

• Antidepressant addition (SSRI often used)
• Certain antipsychotics better (aripiprazole)
• CBT for depression
• Ensure depression not from antipsychotic akinesia

Anxiety

Address with:

• Anxiolytic antipsychotics (quetiapine, olanzapine)
• SSRI addition if severe
• Benzodiazepines short-term only (abuse/dependence risk)
• Relaxation training, CBT

Cognitive Impairment

No specific medication treatment, but:

• Cognitive remediation programs
• Supported employment with accommodations
• Supported education
• Psychoeducation about cognitive changes
• Sleep optimization (improves cognition)

KwikPsych Schizophrenia Treatment

At KwikPsych in Austin, Dr. Monika Thangada, MD provides comprehensive schizophrenia care:

• First-episode psychosis specialization
• Antipsychotic selection and optimization
• Medication management and monitoring
• Clozapine management when indicated
• LAI coordination
• Psychoeducation and family involvement
• Referral to psychosocial services
• Crisis support

Contact KwikPsych:

• Phone: 737-367-1230
• Location: 12335 Hymeadow Dr, Ste 450, Austin, TX 78750
• Telehealth throughout Texas
• Insurance: Aetna, BCBS, Cigna, UHC, Superior/Ambetter, BSW, Oscar, First Health, Optum, Medicare
• Self-pay: $299 initial, $179 follow-up

Crisis: 988 Lifeline